Highest-materiality recent filing
BioNexus Gene Lab CEO urges Malaysia-China biotech co-development at May 21 forum
CEO Sam Tan spoke at the 2026 China-Malaysia Economic Cooperation Outlook Forum in Kuala Lumpur on May 21, 2026.
BioNexus Gene Lab appoints Dr. Muthu Meyyappan as CCO of Fidelion Diagnostics
Dr. Meyyappan appointed CCO of Fidelion effective March 11, 2026; will lead global commercial strategy for VitaGuard MRD platform.
Chemrex board streamlined to two directors: Matthew L. Barsing (Chairman) and Angeline Chong (Director, BioNexus CFO).
BioNexus begins VitaGuard MRD deployment in Southeast Asia; aims to undercut $3,000 legacy tests
Initial deployments in select Southeast Asian medical hubs during 2026; platform targets under $3,000 per test vs legacy costs often exceeding $3,000.
BioNexus Gene Lab Corp. shareholders elect all four director nominees and approve 2025 equity plan
Directors re-elected: Su-Leng Tan Lee, Muhammad Azrul bin Abdul Hamid, Jook Yuen Low, Chee Keong Yap.
Chemrex subsidiary governance shake-up: four directors resign; new chairman appointed
Four Chemrex officers/directors (Too Kam Tham, Liong Tai Tan, Wei Foong Lim, Kuan Yew Tan) resigned on Dec 19, 2025.
ARC Group committed to buy up to $500M of BGLC common stock over 36 months at 3.0-3.5% discount to VWAP; 175k commitment shares issued at $4.32.
BioNexus files $100M shelf, enters $20M ATM with Maxim Group
Enters Equity Distribution Agreement with Maxim Group LLC to sell up to $20M of common stock via ATM.
BGLC enters definitive cross-equity deal for Fidelion's VitaGuard MRD platform in SE Asia
BGLC subscribes for at least 15% of Fidelion shares; issues 19.9% of its common stock to Fidelion.
BioNexus Gene Lab signs non-binding partnership with BirchBioMed for FS2 topical platform in SE Asia
BGLC to lead Birch's $10M financing round; will issue 4.99% of its outstanding common shares to Birch.
BioNexus Gene Lab enters strategic alliance for VitaGuard MRD platform in SE Asia
BGLC to acquire equity stake in Fidelion Diagnostics and exclusive commercial rights to VitaGuard MRD platform across ASEAN.
BioNexus Gene Lab appoints Chong Set Fui as CFO effective immediately
Appointed Chong Set Fui (Angeline) as CFO and Principal Financial Officer, effective June 17, 2025.
BioNexus Gene Lab regains Nasdaq minimum bid price compliance, avoids delisting
Received Nasdaq Panel confirmation on Apr 30, 2025, that BGLC met $1.00 minimum bid price rule.
BioNexus Gene Lab Corp. effects 1-for-10 reverse stock split effective April 7, 2025
1-for-10 reverse split effective 12:01 a.m. ET April 7, 2025; shares reduced from 17,967,663 to 1,796,597.
Reverse stock split at 1-for-10 ratio; effective 12:01 a.m. ET on April 7, 2025.
BioNexus Gene Lab shareholders approve reverse stock split at 1:5 to 1:10 ratio
98.36% of votes cast (4.94B) approved reverse stock split; ratio range of 1:5 to 1:10 at Board discretion.
BGLC partners with ML Tech to optimize Ethereum treasury strategy
Partnership with ML Tech, an NFA-regulated AI wealth management platform, to optimize BGLC's Ethereum holdings.
Board approved Ethereum (ETH) as the primary treasury asset; BGLC is first Nasdaq-listed company to do so.
BioNexus Gene Lab creates Series Z Preferred with 5B votes to facilitate Reverse Stock Split
Created one share of Series Z Preferred Stock with 5,000,000,000 votes, solely on Reverse Stock Split matter.
BioNexus Gene Lab gets Nasdaq extension to May 1, 2025 for bid price compliance; plans reverse split
Nasdaq Hearings Panel grants temporary exception until May 1, 2025 to regain minimum $1.00 bid price.
Received delisting notice on Nov 5, 2024 for failing to maintain minimum $1 bid price after two 180-day grace periods ended Nov 4.
Two directors resign from BioNexus Gene Lab board effective immediately
Wei Foong Lim and Koon Wai Wong resigned as directors on October 9, 2024.
BioNexus Gene Lab alleges unlawful proxy solicitation; stock plan and reverse split fail
Three director nominees re-elected despite significant against votes (Su-Leng Tan Lee: 4.1M for vs 6.3M against).
BioNexus Gene Lab enters biogas sector in Malaysia via partnership with Protech Builders
MRNA Scientific (BGLC subsidiary) and Protech Builders signed a 3-year teaming agreement to develop biogas plants in Malaysia.
BioNexus Gene Lab subsidiary signs outsourcing deal with Vitarray for mRNA detection in SE Asia
Agreement for mRNA dynamic gene detection services targeting Southeast Asian market.
BioNexus Gene Lab invests $450K in color paste production; signs MOU with Shenzhen Rongguang Health
Chemrex invests RM 2M (~$450K) to produce fine-quality color paste for composite industrial customers; operations start Sept 2024.
BioNexus Gene Lab reduces stockholder meeting quorum to one-third
Board adopted amended bylaws on September 4, 2024, effective immediately.
BioNexus Gene Lab (BGLC) announces MyCIF co-investment in AISB, total round RM 1.7M (~$390k)
Malaysian Securities Commission co-invests alongside BGLC in Ascension Innovation under ESI scheme; total round RM 1.7M (~USD 390k).
BioNexus Gene Lab invests RM 1M for equity stake in Ascension Innovation Sdn Bhd
Investment of RM 1 million (~USD 228k) for a significant equity stake in Ascension Innovation Sdn Bhd (AISB).
Base salary for CEO/acting CFO Su-Leng Tan Lee set at $35,000 per month effective July 1, 2024.
Nasdaq grants BioNexus Gene Lab 180-day extension to meet $1 bid price rule through Nov 4, 2024
Initial bid price deficiency notice received Nov 6, 2023; original 180-day cure period expired May 6, 2024.
BioNexus Gene Lab invests RM1.2M for 10% stake in Malaysian digital health firm AISB
Investment of RM1.2M (~$250k) via subsidiary MRNA Scientific for ~10% equity in Ascension Innovation (AISB).
BioNexus Gene Lab removes eight directors, appoints four new directors and new CEO
Stockholders owning 50.1% (17,792,663 shares) approved removal of eight directors and appointment of four new directors via written consent.
BioNexus Gene Lab receives Nasdaq bid-price deficiency notice
Closing bid price below $1.00 for 33 consecutive business days (Sept 20 - Nov 3, 2023).
BioNexus Gene Lab CFO Wei Li Leong resigns effective Oct 30, 2023
Wei Li Leong resigned as CFO effective October 30, 2023; will stay for one additional month.
BioNexus Gene Lab amends 8-K to disclose CEO and CFO are father and daughter
CEO Chi Yuen Leong's daughter, Wei Li Leong, serves as CFO.
Bionexus Gene Lab appoints Chi Yuen Leong as CEO and director, effective Oct 12, 2023
Chi Yuen Leong appointed CEO and director effective October 12, 2023; annual compensation $24,000.
Bionexus Gene Lab CEO Sook Keng Yeoh resigns effective Oct 4; no successor named yet
CEO Sook Keng Yeoh resigned as CEO and director on October 4, 2023.
Bionexus Gene Lab COO Liong Tai Tan resigns; Lee Su-Leng Tan appointed COO
Liong Tai Tan resigned as COO and director effective August 31, 2023; no disagreement with company.
BioNexus closes $5.75M public offering and uplists to Nasdaq
Closed underwritten public offering of 1,437,500 shares at $4.00/share; gross proceeds $5.75M.
BioNexus Gene Lab Corp. completes 1-for-12 reverse stock split effective July 20, 2023
Reverse stock split at 1-for-12 ratio effective July 20, 2023; prior 1-for-10 plan amended.
Bionexus Gene Lab replaces Chairman, CEO, and President in leadership reshuffle
Chairman Soo Kow Lai, CEO Chan Chong Wong, and President Chi Yuen Leong resigned effective Aug 12, 2022; no disagreement cited.
Concurrent with the new appointment, Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.
On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately.
Additionally, the Board has re-appointed Mr. Su-Leng Tan Lee as Secretary of the Company and has appointed him as President, effective immediately.
On November 5, 2024, the Board of Directors of the Company appointed Ms. Jook Yuen Low as an independent director to the Board, effective immediately.
On October 9, 2024, Mr. Wei Foong Lim and Mr. Koon Wai Wong resigned in their capacities as members of the Board of Directors of the Company, effective immediately.
On October 9, 2024, Mr. Wei Foong Lim and Mr. Koon Wai Wong resigned in their capacities as members of the Board of Directors of the Company, effective immediately.
On October 30, 2023, Ms. Wei Li Leong, the Chief Financial Officer (“CFO”), tendered her resignation letter to BioNexus Gene Lab Corp. (the “Company”) from her position at the Company.
On October 12, 2023, the board of directors of the Bionexus Gene Lab Corp. (“the Company”) approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer and a director, effective October 12, 2023.
On October 12, 2023, the board of directors of the Bionexus Gene Lab Corp. (“the Company”) approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer and a director, effective October 12, 2023.
On October 4, 2023, Mr. Sook Keng Yeoh, the Chief Executive Officer and a member of the Board of Directors, tendered his resignation letter to Bionexus Gene Lab Corp. (the “Company”) from his positions at the Company.
The Company and Mr. Liong Tai Tan agreed that the resignations would be effective August 31, 2023.
the Board of Directors of the Company approved the appointment of Mr. Lee Su-Leng Tan as the Chief Operating Officer and not a director, effective September 1, 2023.
Max materiality 0.85 · Median 0.57 · Most common event other_material